United States

Life sciences by the numbers: IPOs, deals, M&A and more


So far in 2019 there have been 57 life sciences companies that have gone through an initial public offering and are actively trading. Those companies raised $12 billion, with the largest being Avantor and Smile Direct Club, representing $4.7 billion of all initial funds raised.

What is interesting this year is that of all the IPOs, 42% were private equity backed and 49% were venture capital backed. This is different from what we have seen over the last three years where 30% were private equity backed and 52% were venture capital backed. That shift seems to be the result of the biotech IPOs, of which 50% were indeed private equity backed this year. We have also seen that there is a significant shift in the amount raised by each sector.

What does this mean for life sciences? Get additional insights on industry growth, deals and more. Check out our brief video below.


Subscribe to Life Sciences newsletter

Contact Our Team

John Lanza
National Life Sciences Practice Leader